Action and use<\/strong><\/p>\n Thiazide diuretic.<\/p>\n Preparations<\/strong><\/p>\n Bendroflumethiazide Tablets<\/p>\n Bendroflumethiazide Oral Suspension<\/p>\n (3RS)-3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.<\/p>\n 98.0 per cent to 102.0 per cent (dried substance).<\/p>\n White or almost white, crystalline powder<\/p>\n Practically insoluble in water, freely soluble in acetone, soluble in ethanol (96 per cent).<\/p>\n Infrared absorption spectrophotometry (2.2.24).<\/p>\n Comparison bendroflumethiazide CRS.<\/p>\n Liquid chromatography (2.2.29). Prepare the solutions immediately before use.<\/p>\n Solvent mixture Mix 40 volumes of methanol R and 60 volumes of a 2.0 g\/L solution of citric acid monohydrate R.<\/p>\n Test solution Dissolve 10.0 mg of the substance to be examined in the solvent mixture and dilute to 50.0 mL with the solvent mixture.<\/p>\n Reference solution (a) Dissolve 2 mg of bendroflumethiazide impurity A CRS and 2.5 mg of altizide CRS in the solvent mixture and dilute to 10 mL with the solvent mixture. Mix 1 mL of this solution with 1 mL of the test solution and dilute to 100 mL with the solvent mixture. Column:<\/p>\n \u2014 size: l = 0.15 m, \u00d8 = 3.0 mm;<\/p>\n \u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n \u2014 temperature: 40 \u00b0C.<\/p>\n Mobile phase: Mix 15 volumes of tetrahydrofuran R, 25 volumes of methanol R and 60 volumes of a 2.0 g\/L solution of citric acid monohydrate R.<\/p>\n Flow rate: 0.8 mL\/min.<\/p>\n Detection: Spectrophotometer at 273 nm.<\/p>\n Injection: 20 \u03bcL.<\/p>\n Run time: Twice the retention time of bendroflumethiazide.<\/p>\n Relative retention: With reference to bendroflumethiazide (retention time = about 8 min): impurity A = about 0.2; altizide = about 0.5.<\/p>\n System suitability: Reference solution (a):<\/p>\n \u2014 resolution: minimum 10 between the peaks due to altizide and bendroflumethiazide.<\/p>\n Limits:<\/p>\n \u2014 impurity A: not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.1 per cent);<\/p>\n \u2014 unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n \u2014 total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent);<\/p>\n \u2014 disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).<\/p>\n Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n Dissolve 0.150 g in 50 mL of dimethyl sulfoxide R. Titrate to the 2 point of inflexion with 0.1 M tetrabutylammonium hydroxide in 2-propanol, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.<\/p>\n 1 mL of 0.1 M tetrabutylammonium hydroxide in 2-propanol is equivalent to 21.07 mg of C15<\/sub>H14<\/sub>F3<\/sub>N3<\/sub>O4<\/sub>S2<\/sub>.<\/p>\n Specified impurities A.<\/p>\n A. 4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. monograph 0370) C15H14F3N3O4S2\u00a0 \u00a0 \u00a0421.4\u00a0 \u00a0 \u00a073-48-3 Action and use Thiazide diuretic. Preparations Bendroflumethiazide Tablets Bendroflumethiazide Oral Suspension DEFINITION (3RS)-3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Content 98.0 per cent to 102.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder Solubility Practically insoluble in water, freely soluble in acetone, soluble in ethanol (96 per…<\/p>\n","protected":false},"author":2,"featured_media":3384,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-3367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/3367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=3367"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/3367\/revisions"}],"predecessor-version":[{"id":5220,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/3367\/revisions\/5220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/3384"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=3367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=3367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=3367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
Content<\/h3>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Solubility<\/h3>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Related substances<\/h2>\n
\nReference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.<\/p>\nLoss on drying (2.2.32)<\/h4>\n
Sulfated ash (2.4.14)<\/h4>\n
ASSAY<\/h2>\n
IMPURITIES<\/h2>\n
![\"Bendroflumethiazide\"](\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/09\/Bendroflumethiazide-A.jpg\")
<\/p>\n